Key Points {#FPar1}
==========

The Prostate Cancer Registry collected real-world data on the clinical characteristics, management, and outcomes of more than 3000 men with metastatic castration-resistant prostate cancer (mCRPC) from 2013--2016.This study found that the efficacy of three major first-line treatments for mCRPC (abiraterone, enzalutamide, and docetaxel) was similar between subpopulations of patients with co-morbidities and the wider patient population.These real-world data provide information on long-term outcomes for patients with metastatic castration-resistant prostate cancer.

Background {#Sec1}
==========

Prostate cancer is the second most common cancer and fifth leading cause of death from cancer in men \[[@CR1]\]. Worldwide, an estimated 1.1 million men were diagnosed with prostate cancer in 2012, representing 15% of all cancers diagnosed in men, and the disease caused 307,000 deaths \[[@CR1]\]. In Europe, 450,000 new cases of prostate cancer were diagnosed in 2018, and 107,000 deaths were reported \[[@CR2]\]. Prostate cancer survival rates vary widely according to stage. Outcomes for localized prostate cancer are very good, owing to effective radical surgery or radiation therapy \[[@CR3]\]. However, the mortality rate among men in whom the disease has progressed to metastatic prostate cancer is substantial. Although several options for treatment of metastatic castration-resistant prostate cancer (mCRPC) (abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T) have shown a survival benefit in phase 3 trials, evidence for optimal sequences or combinations is lacking \[[@CR4]--[@CR6]\]. Expert opinion is helpful for treatment decisions in routine clinical practice \[[@CR7]\]; however, there is a substantial need to improve the understanding and management of this disease---in particular, to avoid progression to disease states in which mortality rates are high and to assess patients outside of a clinical trial setting.

The Prostate Cancer Registry (PCR) (NCT02236637) was initiated in 2013 to collect real-world data on mCRPC treatments. This is the first and largest prospective, international, observational study of patients with mCRPC. The PCR aims to document the characteristics, management, and outcomes of more than 3000 men in routine clinical practice, independent of treatment used. Enrollment took place between June 2013 and March 2016, when unprecedented progress was being made in the treatment of mCRPC in Europe. The PCR provided the opportunity to capture a wealth of data on all mCRPC treatments from this critical period in a wide range of countries and patients, including groups under-represented in clinical research. Thus, the PCR contains important data reflecting clinical practice in these challenging subgroups of patients with mCRPC, for whom data on which to base treatment decisions are often lacking.

This analysis of data in the PCR focuses on the characteristics and clinical outcomes of patients who received their first treatment for mCRPC in routine clinical practice including subgroups with baseline cardiac disease, diabetes mellitus, or visceral metastases. Specifically, baseline patient characteristics, treatment exposure, overall survival (OS), and time to progression were evaluated.

Methods {#Sec2}
=======

Aim, Study Design, and Setting {#Sec3}
------------------------------

This prospective, noninterventional analysis of patient record data from the multicenter PCR of men with mCRPC was conducted to gain a greater understanding of real-world outcomes in a broad group of patients treated for mCRPC to optimize future treatment of patients with this disease. We focused on the characteristics and clinical outcomes of patients, including subgroups with baseline cardiac disease, diabetes mellitus, or visceral metastases, who received their first treatment for mCRPC during participation in the PCR. The data for the PCR were collected at 199 centers specializing in the treatment of prostate cancer by both oncologists and urologists in a range of settings (including hospitals, private clinics, outpatient departments, and universities) in 16 countries: Austria, Belgium, France, Germany, Israel, Italy, Luxembourg, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the UK. Patient enrollment took place between 2013 and 2016. At the start of the PCR, abiraterone acetate and enzalutamide were not routinely available in the mCRPC setting in all 16 countries. The study duration was 5.5 years, with a maximum patient follow-up of 3 years, and was designed specifically to include more than one line of therapy where applicable. The study end date was 9 July 2018.

Patients {#Sec4}
--------

Men aged ≥ 18 years with a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma with mCRPC (disease progression despite testosterone \< 50 ng/dL and/or androgen deprivation therapy and/or history of orchiectomy), enrolled at any time after diagnosis, under surveillance according to routine clinical practice, or who initiated a systemic treatment for mCRPC (as required) following baseline data collection at enrollment, were eligible. The PCR included patients treated with abiraterone acetate plus prednisone or prednisolone (collectively, "abiraterone"), enzalutamide, docetaxel, other chemotherapy, and radium-223. Only treatment groups with adequate numbers of patients (\> 50) for reliable analysis were included. Patients treated with other chemotherapy or radium-223 were excluded because the numbers were too low.

Variables and Data Measurement {#Sec5}
------------------------------

Treatment outcomes were duration of initial therapy and reasons for stopping initial mCRPC therapy. Appropriate treatment gaps for classifying subsequent therapy were 30 days for abiraterone or enzalutamide and 60 days for docetaxel, which included any prolonged, temporary treatment discontinuation. Efficacy outcomes were OS at 3 years after enrollment and time to progression. Criteria for disease progression on treatment (date of recording progression/assessment) were met if: (1) there was evidence of radiographic progression by investigator's assessment (Prostate Cancer Working Group 2 and Response Evaluation Criteria In Solid Tumors guidelines were recommended by the protocol); (2) there was evidence of clinical progression by investigator's assessment (date of the patient visit); (3) first-line mCRPC treatment was stopped because of progression (date treatment stopped); or (4) new mCRPC treatment was started because of progression (date new treatment began). The treatment effects for time to progression with the therapies of interest were compared for the entire analysis population. We compared treatment outcomes in the whole analysis population with those in subgroups of patients with baseline cardiovascular disease requiring treatment (including at least one of the following co-morbidities: hypertension, angina pectoris, history of myocardial infarction, arrhythmia, thromboembolic disease, transient ischemic attack, cerebrovascular accident, and/or other cardiovascular event), diabetes mellitus, or visceral metastases (defined as lesions in the liver and/or lung). These patient subgroups are typically under-represented in clinical studies. Adverse events were collected only for those patients receiving abiraterone, as a regulatory requirement.

We used observational methodology to capture data. The treating physician made treatment decisions at his or her discretion, per routine clinical practice, and only data available from clinical practice were collected. We collected prior disease history and management data at study inclusion and clinical data at study inclusion and prospectively every 3 months during routine follow-up (at least every 3 months per protocol) over the 3-year study period, with clinical-trial levels of monitoring quality (see Supplementary Fig. S1). Because docetaxel is administered through a maximum number of cycles (typically 6--10 cycles as appropriate), outcomes influenced by duration of docetaxel treatment should not be compared with those of abiraterone or enzalutamide. Cause of death data were not collected.

Bias {#Sec6}
----

To ensure a patient population representative of that seen in clinical practice and to reduce selection bias, the protocol stated that all consecutive patients meeting the eligibility criteria at a participating site and who agreed to participate according to local regulations were enrolled in the PCR, irrespective of their treatment.

Study Size {#Sec7}
----------

Of more than 3000 men included in the PCR, data from patients who were being treated with abiraterone, enzalutamide, or docetaxel as first-line mCRPC therapy and who had not received previous systemic mCRPC treatment were included in this analysis. The PCR was designed to generate data for informative purposes. Thus, this sample size was determined by pragmatic considerations, to provide data from a large population that is representative of patients with mCRPC in the Europe/Middle East region.

Statistical Methods {#Sec8}
-------------------

We only used descriptive statistics to present observed data from routine clinical practice. To manage confounding, we used propensity score methods for the comparative effectiveness analyses. We did not apply missing data imputation methods; thus, there were no sensitivity analyses, and subgroups were constructed based on medical criteria (i.e., treatment received, co-morbidities).

Results {#Sec9}
=======

Patients {#Sec10}
--------

At the end of study, 3003 patients were evaluated, 1874 (62.4%) of whom had received no previous mCRPC treatment; of these, 1654 (88.3%) started a treatment documented in the PCR (abiraterone, enzalutamide, docetaxel, other chemotherapy, radium-223, trial medication). Abiraterone, enzalutamide, or docetaxel as first-line mCRPC therapy was received by 754, 227, and 602 patients, respectively, with a median follow-up of 18.6 months. The number of patients and study flow are presented in the Supplementary Material (Fig S2).

Overall and First-Line mCRPC Treatment Population {#Sec11}
-------------------------------------------------

### Baseline Characteristics {#Sec12}

Patient demographics and disease and biological characteristics at study inclusion are shown in Table [1](#Tab1){ref-type="table"}. Patients treated with docetaxel were younger than those treated with abiraterone or enzalutamide (median age \[range\]: 69 \[44--88\] vs. 76 \[43--98\] and 76 \[53--91\] years, respectively) and had a shorter median (range) time from initial diagnosis to study inclusion (2.6 \[0--22\] years vs. 5.0 \[0--29\] years and 4.5 \[0--24\] years, respectively). At diagnosis, de novo metastases were reported in 35.0% of patients in the abiraterone group compared with 42.3% in the enzalutamide group and 50.1% in the docetaxel group. Median (range) time from initial to metastatic diagnosis was 2.5 (0--29), 0.9 (0--21), and 0.1 (0--21) months for the abiraterone, enzalutamide, and docetaxel groups, respectively. In addition, a Gleason score of 8--10 was reported in 51.0%, 60.6%, and 58.4% of patients in the abiraterone, enzalutamide, and docetaxel groups, respectively.Table 1Patient demographics and disease and biological characteristics at study inclusion in the first-line mCRPC treatment populationCharacteristicPatients who had not received previous mCRPC treatment at baseline *N* = 1874First-line treatment withAbiraterone *N* = 754Enzalutamide *N* = 227Docetaxel *N* = 602Age, Mean (SD), years73.1 (8.58)75.3 (8.20)74.9 (7.87)68.8 (7.70) Median (range), years74.0 (43--98)76.0 (43--98)76.0 (53--91)69.0 (44--88)Age group, *n* (%) \< 65 years314 (16.8)81 (10.7)24 (10.6)173 (28.7) 65--74 years683 (36.4)228 (30.2)75 (33.0)280 (46.5) ≥ 75 years877 (46.8)445 (59.0)128 (56.4)149 (24.8)Geographic distribution, *n* (%) *N*1874 (100.0)754 (100.0)227 (100.0)602 (100.0) Austria12 (0.6)2 (0.2)2 (0.9)2 (0.3) Belgium129 (6.9)60 (8.0)25 (11.0)28 (4.7) France209 (11.2)116 (15.4)27 (11.9)53 (8.8) Germany240 (12.8)128 (17.0)19 (8.4)61 (10.1) Israel18 (1.0)11 (1.5)03 (0.5) Italy238 (12.7)157 (20.8)2 (0.9)70 (11.6) Luxembourg8 (0.4)1 (0.1)06 (1.0) Poland163 (78.7)1 (0.1)2 (0.9)122 (20.3) Portugal78 (4.2)21 (2.8)2 (0.9)43 (7.1) Russia79 (4.2)16 (2.1)2 (0.9)27 (4.5) Slovenia22 (1.2)14 (1.9)2 (0.9)1 (0.2) Spain141 (7.5)85 (11.3)17 (7.5)24 (4.0) Sweden149 (8.0)18 (2.4)47 (20.7)38 (6.3) Switzerland14 (0.8)6 (0.8)1 (0.4)7 (1.2) Turkey61 (3.3)10 (1.3)047 (7.8) United Kingdom313 (16.7)108 (14.3)79 (34.8)70 (11.6)ECOG performance status, *n* (%) *N*1732715187555 0746 (43.1)340 (47.6)99 (52.9)211 (38.0) 1797 (46.0)318 (44.5)69 (36.9)293 (52.8)  ≥ 2189 (10.9)57 (8.0)19 (10.2)51 (9.2)Gleason score at initial diagnosis, *n* (%) *N*1713674208574  ≤ 6216 (12.6)100 (14.8)25 (12.0)61 (10.6) 7548 (32.0)230 (34.1)57 (27.4)178 (31.0) 8--10949 (55.4)344 (51.0)126 (60.6)335 (58.4)M stage at initial diagnosis, *n* (%) *N*1830732222591 Mx353 (19.3)161 (22.0)40 (18.0)100 (16.9) M0682 (37.3)315 (43.0)88 (39.6)195 (33.0) M1, M1a, M1b, M1c795 (43.4)256 (35.0)94 (42.3)296 (50.1)Time from initial prostate cancer diagnosis to start of the study *N*1874754227602 Median years (range)3.8 (0--29)5.0 (0--29)4.5 (0--24)2.6 (0--22)Presence of bone metastases (baseline), *n* (%) *N*1396550184451 Any1253 (89.8)548 (99.6)164 (89.1)405 (89.8)  ≥ 5548 (39.3)203 (36.9)60 (32.6)192 (42.6)Visceral metastases (baseline), *n* (%) *N*1484612163517 Liver only69 (4.6)13 (2.1)9 (5.5)39 (7.5) Lung only96 (6.5)39 (6.4)7 (4.3)40 (7.7) Liver and lung17 (1.1)7 (1.1)09 (1.7)Biological parameters PSA, ng/mL *N*1833733226588 Mean (SD)143.66 (462.496)125.54 (488.412)79.82 (173.516)181.05 (510.264)Lactic acid dehydrogenase, U/L *N*73233177242 Mean (SD)344.5 (296.75)330.3 (281.58)283.5 (204.28)367.1 (320.45)Hemoglobin, g/dL *N*1618651199530 Mean (SD)12.6 (1.67)12.7 (1.63)12.9 (1.43)12.5 (1.73)Alkaline phosphatase, U/L *N*1365575191414 Mean (SD)209.6 (341.29)192.1 (282.84)181.8 (473.49)223.7 (297.86)Co-morbidities requiring treatment, *n* (%) Any1367 (72.9)566 (75.1)176 (77.5)398 (66.1) Cardiovascular1221 (65.2)504 (66.8)161 (70.9)351 (58.3)  Hypertension1002 (53.5)411 (54.5)129 (56.8)289 (48.0)  Angina pectoris115 (6.1)34 (4.5)12 (5.3)35 (5.8)  Myocardial infarction133 (7.1)48 (6.4)21 (9.3)32 (5.3)  Arrhythmia154 (8.2)62 (8.2)22 (9.7)41 (6.8)  Thromboembolic disease55 (2.9)21 (2.8)8 (3.5)18 (3.0)  Cerebrovascular accident48 (2.6)19 (2.5)3 (1.3)17 (2.8)  Transient ischemic attack34 (1.8)14 (1.9)5 (2.2)9 (1.5)  Other cardiovascular300 (16.0)139 (18.4)39 (17.2)80 (13.3)Respiratory160 (8.5)60 (8.0)27 (11.9)48 (8.0) Chronic obstructive pulmonary disease105 (5.6)41 (5.4)16 (7.0)29 (4.8) Other respiratory60 (3.2)20 (2.7)12 (5.3)19 (3.2)Renal143 (7.6)52 (6.9)24 (10.6)42 (7.0) Chronic renal disease82 (4.4)31 (4.1)16 (7.0)21 (3.5) Other renal62 (3.3)21 (2.8)8 (3.5)21 (3.5)Hepatic31 (1.7)17 (2.3)3 (1.3)8 (1.3) Chronic hepatic disease17 (0.9)9 (1.2)3 (1.3)4 (0.7) Other hepatic14 (0.7)8 (1.1)04 (0.7)Neurologic157 (8.4)66 (8.8)17 (7.5)41 (6.8) Peripheral sensory impairment8 (0.4)2 (0.3)05 (0.8) Memory impairment14 (0.7)5 (0.7)4 (1.8)2 (0.3) Cognitive disorder12 (0.6)4 (0.5)2 (0.9)1 (0.2) Convulsion5 (0.3)3 (0.4)00 Other neurologic54 (2.9)27 (3.6)4 (1.8)10 (1.7)Infections11 (0.6)6 (0.8)3 (1.3)1 (0.2) Other infection11 (0.6)6 (0.8)3 (1.3)1 (0.2)Diabetes mellitus307 (16.4)121 (16.0)47 (20.7)100 (16.6) Type 2235 (12.5)87 (11.5)36 (15.9)82 (13.6) Type 172 (3.8)34 (4.5)11 (4.8)18 (3.0)Investigations Hypercholesterolemia276 (14.7)122 (16.2)48 (21.1)62 (10.3)*ECOG* Eastern Cooperative Oncology Group, *M* metastatic status, *mCRPC* metastatic castration-resistant prostate cancer, *N* number of evaluable patients for each specific parameter, *PSA* prostate-specific antigen, *SD* standard deviation

Details regarding treatment history at study inclusion are presented in Table [2](#Tab2){ref-type="table"}. Overall, 10.1% and 21.3% of patients had undergone either radical prostatectomy or prostate radiotherapy, respectively, since initial diagnosis (abiraterone, 11.8% and 23.1%; enzalutamide, 9.5% and 23.3%; docetaxel, 9.5% and 23.3%; respectively) and 94.7% had received at least one prior systemic anticancer therapy since diagnosis (95.1%, 93.8%, and 94.2% for patients treated with abiraterone, enzalutamide, and docetaxel, respectively). Orchiectomy had been performed in 4.6%, 7.3%, and 5.3% of patients, respectively.Table 2Treatment history at study inclusion in the first-line mCRPC treatment populationPrior treatment, *n* (%)Patients who had not received previous mCRPC treatment at baseline *n* = 1874First-line treatment withAbiraterone *n* = 754Enzalutamide *n* = 227Docetaxel *n* = 602Orchiectomy since initial diagnosis123 (6.6)35 (4.6)12 (5.3)44 (7.3)Radical prostatectomy/prostate-specific radiotherapy since initial diagnosis Both radical prostatectomy and prostate-specific radiotherapy160 (8.5)79 (10.5)18 (7.9)52 (8.6) Radical prostatectomy only190 (10.1)89 (11.8)21 (9.3)57 (9.5) Prostate-specific radiotherapy only399 (21.3)174 (23.1)46 (20.3)140 (23.3) None1125 (60.0)412 (54.6)142 (62.6)353 (58.6)Prior systemic anticancer therapy Any1774 (94.7)718 (95.2)213 (93.8)567 (94.2) Endocrine therapy1755 (93.6)710 (94.2)211 (93.0)562 (93.4)  Antiandrogen1569 (83.7)646 (85.7)188 (82.8)506 (84.1)  GnRH agonist1280 (68.3)474 (62.9)211 (93.0)434 (72.1)  Steroids194 (10.4)76 (10.1)22 (9.7)75 (12.5)  GnRH antagonist127 (6.8)64 (8.5)9 (4.0)39 (6.5)  Estrogens and derivatives53 (2.8)28 (3.7)7 (3.1)5 (0.8)  Adrenal synthesis inhibitors14 (0.7)6 (0.8)0 (0)7 (1.2)  Other6 (0.3)0 (0)3 (1.3)2 (0.3) Bone-targeted  Any455 (24.3)163 (21.6)32 (14.1)176 (29.2)  Zoledronic acid330 (17.6)120 (15.9)20 (8.8)126 (20.9)  Denosumab103 (5.5)45 (6.0)10 (4.4)32 (5.3)  Other55 (2.9)9 (1.2)6 (2.6)32 (5.3) Other28 (1.5)12 (1.6)5 (2.2)7 (1.2)*GnRH* gonadotropin-releasing hormone, *mCRPC* metastatic castration-resistant prostate cancer

### Treatment Exposure {#Sec13}

The median (95% confidence interval \[CI\]) duration of treatment according to the Kaplan--Meier analysis was 11.2 (9.8--12.2) months with abiraterone, 13.0 (10.4--15.9) months with enzalutamide, and 4.8 (4.4--5.0) months with docetaxel (Supplementary Table S1). In the abiraterone, enzalutamide, and docetaxel groups, the most common reason for stopping treatment was disease progression (72.8%, 67.3%, and 27.0% of patients) (Supplementary Table S2). The proportion of patients who discontinued treatment because of toxicity was 7.1%, 13.5%, and 14.2% in these groups, and death during treatment was reported in 7.2%, 11.1%, and 3.8% of patients, respectively (Supplementary Table S2). In this first-line mCRPC treatment population, 48.7%, 43.6%, and 70.8%, of abiraterone-, enzalutamide-, and docetaxel-treated patients, respectively, went on to receive a subsequent treatment; the most common switch was from abiraterone to docetaxel followed by enzalutamide to docetaxel (Table [3](#Tab3){ref-type="table"}).Table 3Subsequent therapy for the first-line treatment population*n* (%)AbirateroneEnzalutamideDocetaxelFirst treatment set754227602Patients with a next therapy^a^367 (48.7)99 (43.6)426 (70.8)Therapy Abiraterone--17 (17.2)191 (44.8) Docetaxel178 (48.5)42 (42.4)-- Enzalutamide99 (27.0)--116 (27.2) Cabazitaxel4 (1.1)2 (2.0)74 (17.4) Other chemotherapy10 (2.7)1 (1.0)8 (1.9)^a^If treatment was interrupted for less than 30 days (abiraterone or enzalutamide) or 60 days (docetaxel or cabazitaxel), it was defined as continuing. Next therapy could be started immediately following cessation of first-line treatment

### Efficacy Outcomes {#Sec14}

Kaplan--Meier estimates showed that the median (95% confidence interval (CI)) time to progression was 9.6 (8.4--10.8), 10.3 (8.9--13.0), and 7.6 (7.0--8.0) months with abiraterone, enzalutamide, and docetaxel, respectively (Fig. [1](#Fig1){ref-type="fig"}a, Table [4](#Tab4){ref-type="table"}). The treatment effects for time to progression comparing abiraterone versus docetaxel and enzalutamide versus docetaxel were statistically significant (all *p* \< 0.0001; hazard ratio \< 1.0), while those comparing abiraterone versus enzalutamide were not significant (all *p* \> 0.5; hazard ratios \> 1.0) (Table [5](#Tab5){ref-type="table"}). The median (95% CI) OS was 27.1 (25.3--28.9), 27.1 (21.8--32.7), and 27.9 (25.6--31.5) months in the abiraterone, enzalutamide, and docetaxel groups, respectively (Fig. [2](#Fig2){ref-type="fig"}a, Table [6](#Tab6){ref-type="table"}). None of the differences between treatment groups for OS were significant (Table [7](#Tab7){ref-type="table"}).Fig. 1Time to progression in the first-line treatment population (**a**), and cardiovascular (**b**), diabetes mellitus (**c**), and visceral metastases subgroups (**d**). *Abi* abiraterone, *Enz* enzalutamide, *Doc* docetaxelTable 4Time to progression in the first-line treatment population, including subgroupsKaplan--Meier estimates (patients with no progression at end of Registry are censored)AbirateroneEnzalutamideDocetaxelFirst-line treatment population, *N*754227602Median time to progression^a^ (95% CI), months9.6 (8.4--10.8)10.30 (8.9--13.0)7.6 (7.0--8.0)Patients with cardiovascular disease, *N*504161351Median time to progression^a^ (95% CI), months9.7 (8.2--11.2)9.8 (8.0--12.9)7.4 (6.6--7.9)Patients with diabetes mellitus, *N*12147100Median time to progression^a^ (95% CI), months12.0 (9.8--16.4)10.3 (5.5--14.7)7.7 (5.7--9.0)Patients with visceral metastases, *N*59--88Median time to progression^a^ (95% CI), months6.2 (4.8--8.1)--7.8 (6.7--9.9)*CI* confidence interval^a^Criteria for disease progression were met if radiographic progression (progression date is date of the assessment); if no radiographic progression documented then clinical progression per investigator's assessment (progression date is date of the patient visit) was used as the criterion. If no progression was documented using the criteria specified, then stopping medication because of progression (progression date is date that the treatment was stopped) was used as the criterion. New treatment started because of progression (progression date is date that the new treatment began) was used if previous medication was not stopped because of progressionTable 5Unadjusted^a^ and adjusted^b^ treatment effect for time to progression in the first-line treatment populationDependent variableUnadjusted/adjustedComparisonNumber of observationsHazard ratio (95% CI)*p* valueUnadjusted and adjusted treatment effect, time to progression, abiraterone vs. docetaxel (first line) Time to progressionUnadjustedAbiraterone vs. docetaxel*n* = 13560.599 (0.529--0.678) \< 0.0001 Time to progressionUnadjustedAbiraterone vs. docetaxel*n* = 10490.597 (0.519--0.686) \< 0.0001 Time to progressionAdjustedAbiraterone vs. docetaxel*n* = 10490.685 (0.586--0.800) \< 0.0001Unadjusted and adjusted treatment effect, time to progression, enzalutamide vs. docetaxel (first line) Time to progressionUnadjustedEnzalutamide vs. docetaxel*n* = 8290.548 (0.456--0.657) \< 0.0001 Time to progressionUnadjustedEnzalutamide vs. docetaxel*n* = 6740.556 (0.455--0.678) \< 0.0001 Time to progressionAdjustedEnzalutamide vs. docetaxel*n* = 6740.564 (0.455--0.698) \< 0.0001Unadjusted and adjusted treatment effect, time to progression, abiraterone vs. enzalutamide (first line) Time to progressionUnadjustedAbiraterone vs. enzalutamide*n* = 9811.031 (0.867--1.226)0.7302 Time to progressionUnadjustedAbiraterone vs. enzalutamide*n* = 7511.009 (0.833--1.222)0.9277 Time to progressionAdjustedAbiraterone vs. enzalutamide*n* = 7511.040 (0.851--1.271)0.7000*CI* confidence interval^a^The unadjusted analysis is a Cox proportional hazards model with treatment as only predictor^b^The adjusted analysis is similar to the unadjusted but is based on the propensity score method; potential confounders are: age, log of time from diagnosis to castration resistance, log of time from diagnosis to metastasis, log of time from metastasis to study start, log alkaline phosphatase, log prostate-specific antigen, log hemoglobin, Gleason score, diabetes, use of strong analgesics, use of weak analgesics, cardiovascular disease, ECOG status 2--3, ECOG status unknown, prior radical prostatectomy, T class 3, T class 4, T class unknown, N class 1, N class unknown, M class 1, M class unknown, bone lesions 5--20, bone lesions \> 20, and bone lesions unknownFig. 2Overall survival in the first-line treatment population (**a**), and cardiovascular (**b**), diabetes mellitus (**c**), and visceral metastases subgroups (**d**). *Abi* abiraterone, *Enz* enzalutamide, *Doc* docetaxelTable 6Overall survival in the first-line treatment population, including subgroupsAbirateroneEnzalutamideDocetaxelFirst-line treatment population, *N*754227602Median overall survival (95% CI), months27.1 (25.3--28.9)27.1 (21.8--32.7)27.9 (25.6--31.5)Patients with cardiovascular disease, *N*504161351Median overall survival (95% CI), months27.4 (23.0--30.3)26.1 (18.1--33.9)26.1 (23.0--29.7)Patients with diabetes mellitus, *N*12147100Median overall survival (95% CI), months30.8 (21.7--NE)27.1 (14.7--NE)24.3 (16.1--29.0)Patients with visceral metastases, *N*59--88Median overall survival (95% CI), months17.40 (13.60--22.70)--20.40 (15.10--26.10)Patients alive at end of Registry are censored*CI* confidence interval, *N* number of evaluable patients for each specific parameter, *NE* not estimableTable 7Unadjusted^a^ and adjusted^b^ treatment effect for overall survival in the first-line treatment populationDependent variableUnadjusted/adjustedComparisonNumber of observationsHazard ratio (95% CI)*p* valueUnadjusted and adjusted treatment effect, overall survival, abiraterone vs. docetaxel (first line) Overall survivalUnadjustedAbiraterone vs. docetaxel*n* = 13561.035 (0.891--1.202)0.6520 Overall survivalUnadjustedAbiraterone vs. docetaxel*n* = 10490.994 (0.841--1.176)0.9462 Overall survivalAdjustedAbiraterone vs. docetaxel*n* = 10491.105 (0.920--1.328)0.2843Unadjusted and adjusted treatment effect, overall survival, enzalutamide vs. docetaxel (first line) Overall survivalUnadjustedEnzalutamide vs. docetaxel*n* = 8291.047 (0.843--1.301)0.6763 Overall survivalUnadjustedEnzalutamide vs. docetaxel*n* = 6741.064 (0.841--1.347)0.6039 Overall survivalAdjustedEnzalutamide vs. docetaxel*n* = 6741.075 (0.837--1.380)0.5727Unadjusted and adjusted treatment effect, overall survival, abiraterone vs. enzalutamide (first line) Overall survivalUnadjustedAbiraterone vs. enzalutamide*n* = 9810.983 (0.798--1.211)0.8741 Overall survivalUnadjustedAbiraterone vs. enzalutamide*n* = 7510.927 (0.737--1.165)0.5147 Overall survivalAdjustedAbiraterone vs. enzalutamide*n* = 7511.000 (0.788--1.270)0.9986*CI* confidence interval^a^The unadjusted analysis is a Cox proportional hazards model with treatment as only predictor^b^The adjusted analysis is similar to the unadjusted, but is based on the propensity score method; potential confounders are: age, log of time from diagnosis to castration resistance, log of time from diagnosis to metastasis, log of time from metastasis to study start, log alkaline phosphatase, log prostate-specific antigen, log hemoglobin, Gleason score, diabetes, use of strong analgesics, use of weak analgesics, cardiovascular disease, ECOG status 2--3, ECOG status unknown, prior radical prostatectomy, T class 3, T class 4, T class unknown, N class 1, *N* class unknown, M class 1, M class unknown, bone lesions 5--20, bone lesions \> 20, and bone lesions unknown

Patients with Cardiovascular Disease {#Sec15}
------------------------------------

### Baseline Characteristics {#Sec16}

At baseline, cardiovascular disease was reported in 504 (66.8%), 161 (70.9%), and 351 (58.3%) patients in the abiraterone, enzalutamide, and docetaxel, groups, respectively; the most common cardiovascular co-morbidity was hypertension in all three treatment groups (54.5%, 56.8%, and 48.0%, respectively), followed by specific cardiovascular co-morbidities of arrhythmia and history of myocardial infarction (Table [1](#Tab1){ref-type="table"}). This cardiovascular disease group also had important concomitant co-morbidities for patients receiving abiraterone, enzalutamide, and docetaxel: diabetes mellitus (types 1 and 2) was reported in 101 (20.0%), 36 (22.4%), and 84 (23.9%) patients; respiratory co-morbidities were reported in 46 (9.1%), 23 (14.3%), and 38 (10.8%) patients; and neurologic co-morbidities were reported in 52 (10.3%), 17 (10.6%), and 37 (10.5%) patients, respectively (Supplementary Table S3A).

Patients treated with abiraterone had a median (range) time from initial prostate cancer diagnosis to study inclusion of 5.3 (0--29) years versus 4.9 (0--21) and 3.1 (0--22) years for the enzalutamide and docetaxel groups, respectively. Median (range) age at baseline was 77 (50--94), 77 (59--91), and 71 (47--88) years, respectively (Supplementary Table S3A), which was older than the ages reported in recent registration studies \[[@CR8], [@CR9]\]. At diagnosis, 49.8%, 59.0%, and 56.6% of patients in the abiraterone, enzalutamide, and docetaxel groups, respectively, had a Gleason score of 8--10 (Supplementary Table S3A). Details regarding treatment history at study inclusion are presented in Supplementary Table S3B.

### Treatment Exposure {#Sec17}

Median (95% CI) treatment durations were 11.1 (9.5--12.7) months with abiraterone, 12.7 (9.1--15.3) months with enzalutamide, and 4.6 (4.3--5.0) months with docetaxel for typically 6--10 cycles (Supplementary Table S1); these are similar to durations observed in the equivalent overall patient population treatment groups, in which docetaxel exposure was shorter than abiraterone and enzalutamide exposures. In the abiraterone, enzalutamide, and docetaxel groups, the most common reason for stopping treatment was disease progression (72.0%, 62.7%, and 24.3% of patients, respectively) (Supplementary Table S2). Death during treatment was reported in 6.9%, 11.9%, and 5.6% of patients in these treatment groups, respectively (Supplementary Table S2).

### Efficacy Outcomes {#Sec18}

According to Kaplan--Meier estimates, the median (95% CI) time to progression was 9.7 (8.2--11.2), 9.8 (8.0--12.9), and 7.4 (6.6--7.9), months for abiraterone, enzalutamide, and docetaxel, respectively (Fig. [1](#Fig1){ref-type="fig"}b, Table [4](#Tab4){ref-type="table"}). The median (95% CI) OS was 27.4 (23.0--30.3), 26.1 (18.1--33.9), and 26.1 (23.0--29.7) months in these treatment groups, respectively (Fig. [2](#Fig2){ref-type="fig"}b, Table [6](#Tab6){ref-type="table"}).

Patients with Diabetes Mellitus {#Sec19}
-------------------------------

### Baseline Characteristics {#Sec20}

At baseline, 121 (16.0%), 47 (20.7%), and 100 (16.6%) patients had diabetes mellitus in the abiraterone, enzalutamide, and docetaxel groups, respectively; in each treatment group, a lower proportion of those with diabetes mellitus had diabetes mellitus type 1 than diabetes mellitus type 2 (71.9% vs. 28.1%, 76.6% vs. 23.4%, and 82.0% vs. 18.0% in the abiraterone, enzalutamide, and docetaxel groups, respectively) (Table [1](#Tab1){ref-type="table"}).

The median (range) time from initial diagnosis to study start was 5.7 (0--29), 4.0 (0--18), and 5.4 (1--20) years in the abiraterone, enzalutamide, and docetaxel groups, respectively. Median (range) age at baseline was 77.0 (54--93), 77.0 (62--91), and 69.0 (51--88) years, respectively (Supplementary Table S4A). A Gleason score of 8--10 at diagnosis was reported in 47.7%, 55.8%, and 49.0% of these treatment groups, respectively (Supplementary Table S4A). The following important concomitant co-morbidity types were reported in the diabetes mellitus group for patients receiving abiraterone, enzalutamide, and docetaxel, respectively: cardiovascular in 102 (84.3%), 36 (76.6%), and 85 (85.0%) patients; neurologic in 13 (10.7%), 4 (8.5%), and 12 (12.0%) patients; and renal in 10 (8.3%), 12 (25.5%), and 7 (7.0%) patients (Supplementary Table S4A). Details regarding treatment history at study inclusion are presented in Supplementary Table S4B.

### Treatment Exposure {#Sec21}

Median (95% CI) treatment duration was 11.5 (9.1--16.1), 12.2 (8.2--17.5), and 4.3 (3.6--4.9) months in the abiraterone, enzalutamide, and docetaxel (typically 6--10 cycles) treatment groups, respectively (Supplementary Table S1), which was similar to that in treatment groups for the overall population, in which docetaxel exposure was shorter than for abiraterone and enzalutamide. The most commonly reported reason for stopping treatment in abiraterone-, enzalutamide-, and docetaxel-treated patients was disease progression (66.3%, 57.9%, and 24.0%, respectively), followed by toxicity (12.0%, 13.2%, and 19.0%, respectively) (Supplementary Table S2). Death during treatment was reported in 9.8%, 18.4%, and 5.6% of patients, respectively (Supplementary Table S2).

### Efficacy Outcomes {#Sec22}

According to Kaplan--Meier estimates, the median (95% CI) time to progression was 12.0 (9.8--16.4), 10.3 (5.5--14.7), and 7.7 (5.7--9.0) months with abiraterone, enzalutamide, and docetaxel, respectively (Fig. [1](#Fig1){ref-type="fig"}c, Table [4](#Tab4){ref-type="table"}). The median (95% CI) OS was 30.8 (21.7--not estimable \[NE\]), 27.1 (14.7--NE), and 24.3 (16.1--29.0) months in these treatment groups, respectively (Fig. [2](#Fig2){ref-type="fig"}c, Table [6](#Tab6){ref-type="table"}).

Patients with Visceral Metastases {#Sec23}
---------------------------------

### Baseline Characteristics {#Sec24}

Visceral metastases were reported in 59 patients (7.8%) in the abiraterone group, 16 (7.0%) in the enzalutamide group, and 88 (14.6%) in the docetaxel group. The small number of patients with visceral metastases in the enzalutamide group meant that meaningful analyses could not be performed (Table [1](#Tab1){ref-type="table"}). Details regarding patient demographics and disease and biological characteristics at study inclusion in patients with visceral metastases in the first-line treatment population and treatment history are presented in Supplementary Tables S5A and S5B, respectively.

### Treatment Exposure {#Sec25}

The median (95% CI) treatment duration in abiraterone- and docetaxel-treated patients was 7.9 (5.5--10.9) and 4.3 (3.5--5.1) months, respectively (Supplementary Table S1); the typical regimen for docetaxel treatment was 6--10 cycles. In this subgroup analysis, 10.4% and 11.6% of patients discontinued abiraterone and docetaxel treatment, respectively, because of toxicity; the most common reason was disease progression (70.8% and 26.7%), with 10.4% and 4.7% of patients dying (Supplementary Table S2). This compares to 7.4%, 72.8%, and 7.2%, for toxicity, disease progression, and death, respectively, during treatment in the whole abiraterone treatment group and 14.2%, 27.0%, and 3.8% in the whole docetaxel group (Supplementary Table S2).

### Efficacy Outcomes {#Sec26}

In patients with visceral metastases, the median (95% CI) time to progression was 6.2 (4.8--8.1) and 7.8 (6.7--9.9) months with abiraterone and docetaxel, respectively (Fig. [1](#Fig1){ref-type="fig"}d, Table [4](#Tab4){ref-type="table"}). The median (95% CI) OS was 17.40 (13.60--22.70) and 20.40 (15.10--26.10) months in abiraterone- and docetaxel-treated patients, respectively -- shorter than in the respective overall patient populations (Fig. [2](#Fig2){ref-type="fig"}d, Table [6](#Tab6){ref-type="table"}).

Discussion {#Sec27}
==========

The data in the PCR provide the first opportunity to evaluate characteristics and outcomes of the largest cohort of patients with mCRPC receiving first-line treatment in the real-world setting. Notably, they encompass information from patients from 16 countries included in the PCR between 2013 and 2016.

In this analysis of a real-world setting, patients treated with docetaxel as their first-line systemic mCRPC treatment were younger than those treated with abiraterone or enzalutamide and had a shorter time from initial diagnosis to inclusion in the study. In addition, a higher proportion of patients in the docetaxel group had an Eastern Cooperative Oncology Group score of 1, visceral metastases, five or more bone metastases at baseline, and had de novo metastases at initial diagnosis. Biological parameters of prostate-specific antigen, lactate dehydrogenase, and alkaline phosphatase levels also tended to be higher in patients treated with docetaxel than in those who received the other treatment options. Together, these findings suggest that the patients treated with docetaxel had more advanced disease and poorer prognosis. These differences in baseline characteristics are not unexpected, given the observational methodology used to capture the treatment decisions made at the discretion of the treating physician. The clinical efficacy and safety of docetaxel therapy in prostate cancer was achieved with a recommended dose of 75 mg/m^2^ every 3 weeks over 10 cycles \[[@CR10]\]; the median duration of docetaxel treatment was approximately 4 months in the patient groups in the analysis. In contrast, the recommended dose of abiraterone was 1000 mg once daily \[[@CR11]\], and the usual dose of enzalutamide is 160 mg taken at the same time once daily \[[@CR12]\]. In general, treatment duration was not influenced by the presence of cardiovascular disease or diabetes mellitus in this study.

In this real-world analysis, which includes patients who are under-represented in prostate cancer clinical trials, median OS of those enrolled in the PCR treated with first-line abiraterone, enzalutamide, or docetaxel as mCRPC therapy was 27.1, 27.1, or 27.9 months, respectively, compared with a median OS of 34.7 months for patients treated with abiraterone acetate in the phase 3 COU-AA-302 study in asymptomatic or mildly symptomatic patients with chemotherapy-naive prostate cancer \[[@CR13]\] and 18.9 months with three-times-weekly docetaxel in patients with metastatic hormone-refractory prostate cancer in the phase 3 TAX 327 study \[[@CR9]\]. However, at the time of the TAX 327 study, subsequent treatment options for mCRPC were limited, which may have influenced the OS rates in this study. In the FIRSTANA study, which evaluated cabazitaxel versus docetaxel treatment in chemotherapy-naïve patients with mCRPC, median OS was 24.3 months for docetaxel \[[@CR14]\], which is similar to our findings. This study was initiated at a time when novel hormonal treatments were being used clinically to treat mCRPC after docetaxel.

In the phase 3 PREVAIL study of enzalutamide in patients with disease progression despite androgen-deprivation therapy, median OS was longer, at 32.4 months \[[@CR8]\]. However, the older age, presence of certain baseline characteristics (visceral metastases, ECOG status of 2 and above), and longer disease duration before treatment of patients in the PCR compared with those in the clinical trials is likely to have affected treatment outcomes. Similarly, shorter OS in renal cancer has been reported for sunitinib in the non-clinical trial setting (18.7 months) compared with the first-line clinical setting (26.4 months) \[[@CR15]\]. Treatment outcomes for mCRPC did not appear to be compromised by cardiovascular disease and diabetes mellitus in the present study; however, in patients with visceral metastases, OS was approximately 7 months shorter than in the overall population.

Data from the PCR provide information on patient subgroups that are poorly represented in pivotal trials. Notably, the PCR provides information on many patients with cardiovascular co-morbidities and patients with both cardiovascular and diabetic co-morbidities. The PCR does not provide information on the severity of the co-morbidities or whether patients' conditions related to co-morbidities at baseline were well controlled by concomitant medications at baseline, which may affect their outcomes. Other than disease progression, toxicity was the next most common reason for stopping systemic mCRPC treatment in patients with cardiovascular disease (8.9% and 16.7% of patients treated with abiraterone and enzalutamide, respectively). This was also a reason for stopping treatment in patients with diabetes mellitus (12.0% and 13.2% stopped abiraterone and enzalutamide, respectively). In addition, the higher incidence of treatment-limiting toxicity in patients with diabetes mellitus compared with the overall population and in patients with cardiovascular disease suggests that extra care should be taken in treating these men.

This study benefits from a number of strengths, including robust monitoring providing clinical trial-level quality data, the size and scope of the Registry, allowing for a large amount of data to be collected, inclusion of patient subgroups under-represented in clinical trials, and a duration that allows mature data to be collected during a period that has seen a number of advances in mCRPC treatment. Furthermore, this is the largest data set on abiraterone treatment in patients with CRPC with visceral metastases in the real-world setting. However, several limitations exist. This is an observational study, and there is no randomization to allow direct treatment comparisons. In addition, because treatment followed clinical practice, duration of exposure varied between treatments based on treatment cycles. Thus, the results for duration of treatment and reason for stopping treatment or number of deaths during the treatment period cannot be compared between docetaxel and abiraterone or docetaxel and enzalutamide because of the possible influence of the dosing regimens of the drugs; docetaxel has a shorter dosing regimen, being administered in 6--10 cycles, compared with the daily regimens of abiraterone acetate and enzalutamide, which are administered until the point of disease progression. Data were also collected at routine clinical visits, which may not have occurred at regular intervals for all patients. The commercial availability of the treatments in participating countries, different treatment practices and settings, and timing of enrollment should also be taken into consideration; the treatment options available in each country of the PCR varied according to availability of different drugs, which may have influenced findings.

Conclusions {#Sec28}
===========

This analysis shows for the first time the effectiveness in parallel of three major treatments in first-line mCRPC therapy: abiraterone, enzalutamide, and docetaxel. More importantly, the efficacy of these treatments was similar among subpopulations of patients with co-morbidities such as cardiovascular disease or diabetes mellitus compared with the wider patient group. For the subpopulation of patients with visceral metastases, outcomes were as expected considering the poor prognosis for this subgroup. This real-world analysis of long-term efficacy outcomes of patients in the PCR provides meaningful data to support physicians in managing different patient groups with mCRPC, which is associated with poor prognosis and mortality. Because the PCR includes patients from several countries and represents real-world practice, these results apply to most men with mCRPC.
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